维生素D缺乏与代谢相关脂肪性肝病的关系  

Research advances in vitamin D deficiency and metabolic associated fatty liver disease

作　　者：罗玲 廖献花[1] 钟碧慧[1] LUO Ling;LIAO Xianhua;ZHONG Bihui(Department of Gastroenterology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院消化内科,广州510080

出　　处：《临床肝胆病杂志》2022年第7期1641-1645,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金资助项目(81870404,81670518,81170392);广东省科技计划项目(2017A020215015,2014A020212118);广东省医学科研基金(A2019496);中国肝炎防治基金会(TQGB20140083)。

摘　　要：代谢相关脂肪性肝病(MAFLD)为全球第一大慢性肝病,但发病机制仍不明确,尚缺乏有效的治疗药物。介绍了MAFLD患者常伴有维生素D缺乏,维生素D可能通过影响糖脂代谢、炎症信号通路、免疫调节、肠道微生态等多种途径参与MAFLD的发生发展。提出维生素D有望成为MAFLD的治疗药物,临床上需关注MAFLD患者维生素D水平的监测和管理,但其内在机制、具体补充剂量及疗程亟待深入探索。Metabolic associated fatty liver disease(MAFLD)is the largest chronic liver disease in the world.Its pathogenesis remains unclear and there is still a lack of effective drugs.This article introduces vitamin D deficiency commonly observed in patients with MAFLD,and it is pointed out that vitamin D may participate in the development and progression of MAFLD through various pathways such as glucose and lipid metabolism,inflammatory signaling pathways,immune modulation,and intestinal microecology.It is proposed that vitamin D supplement is expected to become an effective drug for the treatment of MAFLD,and the monitoring and management of vitamin D level should be taken seriously for MAFLD patients in clinical practice.Further studies are needed to explore its underlying mechanism,dose for supplementation,and course of treatment.

关 键 词：代谢相关脂肪性肝病 维生素D 受体 骨化三醇 

分 类 号：R575.5[医药卫生—消化系统]